Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Saturday, August 1, 2026.
Forward PE Ratio (N/A) = Close Price ($0.61) / Consensus Forward EPS ($-10.64)
FORWARD PE RATIO
N/A
23andMe Holding Co.
Market Cap
$15.31M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | N/A |
| NRC Health (NRC)vs › | $439.69M | 22.17 |
| Shoulder Innovations, Inc. (SI)vs › | $471.59M | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.21B | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.64B | 42.87 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.68B | 9.43 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.19B | N/A |
| Tempus AI, Inc. (TEM)vs › | $7.69B | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.09B | 28.29 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.80B | 35.99 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
At today's $0.61 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-03-31 | $-7.80 | $-7.80 – $-7.80 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
